Skip to content

Study on the safety and efficacy of bupivacaine liposomes in peripheral nerve blockade of anterior and posterior capsule of hip joint

Study on the safety and efficacy of bupivacaine liposomes in peripheral nerve blockade of anterior and posterior capsule of hip joint

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092441
Enrollment
Unknown
Registered
2024-11-15
Start date
2025-01-09
Completion date
Unknown
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Geriatric orthopedic anesthesia

Interventions

Experimental group:Anterior and posterior capsule block group of hip joint
Control group:Anterior capsular block group of hip joint

Sponsors

Yuying Children's Hospital, the Second Affiliated Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Patients planning to undergo total hip replacement surgery, 2. Age range of 60-80 years old, 3. ASA levels I-III; 4. Body Mass Index (BMI): 18-28 kg/m^2; 5. The estimated surgical time is within 120 minutes; 6. Bleeding is expected to be within 300ml.

Exclusion criteria

Exclusion criteria: 1. Patients with contraindications to regional anesthesia; 2. Patients who are allergic to various anesthetic drugs; 3. Patients with clotting time and platelet count abnormal; 4. Patients with cognitive dysfunction before surgery; 5. The puncture area is infected.

Design outcomes

Primary

MeasureTime frame
Quality of postoperative recovery score (QoR-15 score);

Secondary

MeasureTime frame
Resting NRS score at PACU;Sufentanil consumption at PACU;Postoperative resting and exercise NRS scores;Postoperative quadriceps muscle strength;Consumption of sufentanil in intravenous analgesia pump;Total compression times, effective compression times and ineffective compression times in intravenous analgesia pump;Use of parecoxib in wards;Length of hospitalization;First postoperative movement time;PACU Observation Time;Postoperative adverse reactions;

Countries

China

Contacts

Public ContactNan Yang

Yuying Children's Hospital, the Second Affiliated Hospital of Wenzhou Medical University

nay0000@163.com+86 139 5774 3658

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 22, 2026